Does Rallies show Form 4 insider transactions for NAMS?

Yes. Rallies tracks NAMS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NAMS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NAMS. It does not provide personalized investment advice.

NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares) Stock Analysis - Insider Trades

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is a publicly traded Healthcare sector company. As of May 20, 2026, NAMS trades at $35.77 with a market cap of $3.99B and a P/E ratio of -20.07. NAMS moved +6.11% today. Year to date, NAMS is +6.78%; over the trailing twelve months it is +84.75%. Its 52-week range spans $14.06 to $42.21. Analyst consensus is strong buy with an average price target of $48.00. Rallies surfaces NAMS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NAMS stock inside the company?

Recent NAMS insider activity includes LANGE LOUIS G sold 44.17K, LANGE LOUIS G sold 446, Kastelein Johannes Jacob Pieter sold 101.41K, LANGE LOUIS G sold 28.19K, and Kastelein Johannes Jacob Pieter sold 94.12K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NAMS Key Metrics

Key financial metrics for NAMS
Metric	Value
Price	$35.77
Market Cap	$3.99B
P/E Ratio	-20.07
EPS	$-1.79
Dividend Yield	0.00%
52-Week High	$42.21
52-Week Low	$14.06
Volume	1.15M
Avg Volume	0
Revenue (TTM)	$22.57M
Net Income	$-212.73M
Gross Margin	0.00%

Recent NAMS Insider Trades

LANGE LOUIS G sold 44.17K (~$1.34M) on Mar 11, 2026.
LANGE LOUIS G sold 446 (~$13.93K) on Mar 11, 2026.
Kastelein Johannes Jacob Pieter sold 101.41K (~$3.07M) on Mar 9, 2026.
LANGE LOUIS G sold 28.19K (~$828.95K) on Mar 6, 2026.
Kastelein Johannes Jacob Pieter sold 94.12K (~$2.85M) on Mar 6, 2026.

Latest NAMS News

NewAmsterdam Pharma Secures $707.3M Cash, Eyes 2H26 Approvals and 4Q26 Launches — May 7, 2026
NewAmsterdam Pharma to Share BROADWAY Kidney, Safety and LDL Particle Data at ACC.26 — Mar 23, 2026
NewAmsterdam Pharma Reports $728.9M Cash, EMA Decisions Expected H2 2026 — Feb 18, 2026

NAMS Analyst Consensus

11 analysts cover NAMS: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $48.00.

Common questions about NAMS

Who is trading NAMS stock inside the company?: Recent NAMS insider activity includes LANGE LOUIS G sold 44.17K, LANGE LOUIS G sold 446, Kastelein Johannes Jacob Pieter sold 101.41K, LANGE LOUIS G sold 28.19K, and Kastelein Johannes Jacob Pieter sold 94.12K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NAMS?: Yes. Rallies tracks NAMS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NAMS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NAMS. It does not provide personalized investment advice.